|
May 18, 2009 - China Biologic Products, Inc. (OTC
Bulletin Board: CBPO) ("China Biologic," or the "Company"), one of the
leading plasma-based pharmaceutical companies in the People's Republic of China
("PRC"), reported strong financial results for the first quarter of 2009.
First Quarter 2009 Highlights; Revenues increased 169.4%
year-over-year to a record $21.1 million.
"We are pleased to report exceptional revenue and net income results for our
first quarter of 2009 as 'The New China Biologic Products'," said Mr. Chao Ming
Zhao, CEO of China Biologic Products. "During the first quarter, we completed
the government approval process for the transfer of 35% equity interest in Xi'an
Huitian Blood Products Co., Ltd. We recently also completed the acquisition of a
90% controlling interest in Chongqing Dalin Biologic Technologies Co., Ltd.,
which owns 54% of the equity interest in Qianfeng Biologic Products Co., Ltd.
Both of these acquisitions combined have transformed China Biologic into the
largest non-state-owned plasma-based biopharmaceutical company in China.
About China Biologic Products, Inc.
China Biologic Products, Inc. (the "Company"), through its indirect
majority-owned subsidiary, Shandong Taibang Biological Products Co. Ltd., and
equity investments in Xi'an Huitian Blood Products Co., Ltd. and Chongqing Dalin
Biologic Technologies Co., Ltd. is currently the largest non-state-owned
plasma-based biopharmaceutical company approved by the Chinese government. The
Company is a fully integrated biologic products company with plasma collection,
production and manufacturing, research and development, and commercial
operations. The Company's blood products are irreplaceable in the application of
medical emergencies, and prevention and treatment for various diseases. It sells
its plasma-based biopharmaceutical products to hospitals and other healthcare
facilities in China.
Contact:
Web Site:
http://www.chinabiologic.com.
Source. |
